The genetic epidemiology of BRCA1

Easton, D.F.; Narod, StevenA; Ford, Deborah; Steel, Michael

doi:10.1016/s0140-6736(94)92256-x

Cited by 81 publications

(14 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oophorectomy is used as a prophylactic measure and may also be used in the treatment of breast cancer. Our risks are similar to those of the Breast-Cancer Linkage Consortium (BCLC), who estimate risks of 87% for breast cancer, and 44% for ovarian cancer to age 70 (Easton et al, 1994(Easton et al, , 1995. Our estimate of ovariancancer penetrance is higher, but each of our families was selected because it contains at least one case of ovarian cancer.…”

Section: Discussionsupporting

confidence: 79%

Risk modifiers in carriers of brca1 mutations

Narod

Goldgar

Cannon‐Albright

et al. 1995

Intl Journal of Cancer

149

View full text Add to dashboard Cite

The majority of, but not all, women with mutations in the BRCA1 gene will be affected with breast or ovarian cancer by the age of 70. To establish whether known risk factors modify susceptibility to cancer in these women, we have studied the reproductive histories of 333 North American women who were found by haplotype analysis to carry BRCA1 mutations. An increased risk for breast cancer was associated with low parity and with recent birth cohort. The risk of ovarian cancer decreased with increasing age at last childbirth; however, in contrast to the case for sporadic cancer, the risk of ovarian cancer in BRCA1 carriers was found to increase significantly with increasing parity.

show abstract

Section: Discussionsupporting

confidence: 79%

Risk modifiers in carriers of brca1 mutations

Narod

Goldgar

Cannon‐Albright

et al. 1995

Intl Journal of Cancer

149

View full text Add to dashboard Cite

show abstract

“…We do not know to what extent available variables reflect alcohol intake [20,21], food intake [22] or health consciousness, and we do not have any information on genetic predisposition to breast cancer (e.g. presence of a mutation in BRCA1 [23][24][25] or BRCA2 [26,27]). …”

Section: Discussionmentioning

confidence: 99%

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

et al. 2009

View full text Add to dashboard Cite

In Sweden, during 2006 and 2007, women using insulin glargine alone (no other types of insulin) had an increased incidence rate of breast cancer as compared with women using types of insulin other than insulin glargine. This result may be due to a random fluctuation; the possibilities for examining validity are limited, and no statistically significant results were obtained for any other individual cancer site or for the outcome 'all malignancies'. No definitive conclusions regarding a possible causal relationship between insulin glargine use and the occurrence of malignancies can be drawn from the results of this study.

show abstract

“…The gene has been cloned and some of its many mutations described (Easton et al, 1994;Ponder, 1994). A second gene BRCA2 has been located (Wooster et al, 1994).…”

Section: Introductionmentioning

confidence: 99%

“…It is rarely expressed in men. In some families BRCA1 mutations may confer increased risk of other cancers--colon (in both sexes), and prostate (in men) (Ford et al, 1994). Because of BRCAI's association with "female" diseases and its low penetrance in men, it is sometimes difficult for family members to understand the inheritance of the gene in men and women .…”

Section: Introductionmentioning

confidence: 99%